GlassScriptPhysician profile
Ashley M Fields
NPI 1588323596
$1,581.34
in general payments reported to CMS, 2019-2025
18 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.62 · 2022: $66.22 · 2023: $334 · 2024: $628 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $835.64 | 2023-2025 | Relistor |
| Abbvie INC. | $122.61 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $115.56 | 2023-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $112.51 | 2025 | Prospera |
| Novartis Pharmaceuticals Corporation | $70.25 | 2022-2023 | |
| Ibsa Pharma INC. | $54.56 | 2023-2024 | Tirosint, Licart, Tirosint |
| Rigel Pharmaceuticals, INC. | $44.66 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $32.22 | 2023 | Imbruvica |
| Averitas Pharma INC. | $28.57 | 2023-2025 | Qutenza |
| Seagen INC. | $27.21 | 2022-2023 | Tukysa |
| Incyte Corporation | $20.18 | 2023 | Jakafi |
| Amgen INC. | $18.30 | 2023 | Lumakras |
| Ethicon US, LLC | $17.81 | 2025 | Vistaseal |
| Vertex Pharmaceuticals Incorporated | $17.72 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $16.96 | 2023 | |
| Lilly USA, LLC | $15.17 | 2023 | Verzenio, Retevmo, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $13.84 | 2023 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.